The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
Braz. j. med. biol. res
;
46(7): 607-613, ago. 2013. tab, graf
Artículo
en Inglés
| LILACS
| ID: lil-682399
ABSTRACT
Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitro and in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pylori treatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263). Pooled H. pylori eradication rates were 79.03% (95%CI 75.73-82.07) and 68.33% (95%CI 64.44-72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis). The odds ratio (OR) was 1.82 (95%CI 1.17-2.81), the occurrence of total side effects was 15.23% (95%CI 12.58-18.20) and 27.17% (95%CI 23.64-30.92) for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI 0.26-0.77). In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR 1.78, 95%CI 1.16-2.73, P<0.001). However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Helicobacter pylori
/
Infecciones por Helicobacter
/
Fluoroquinolonas
/
Antibacterianos
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio pronóstico
/
Revisiones Sistemáticas Evaluadas
Límite:
Humanos
Idioma:
Inglés
Revista:
Braz. j. med. biol. res
Asunto de la revista:
Biologia
/
Medicina
Año:
2013
Tipo del documento:
Artículo
/
Documento de proyecto
País de afiliación:
China
Institución/País de afiliación:
Fudan University/CN
Similares
MEDLINE
...
LILACS
LIS